Liver Disease Clinical Trials

Showing 81-100 of 1,279 trials

Stimulating Fat Tissue Storage With Niacin to Reduce Fat Accumulation in the Liver.

NCT06843148

Metabolic dysfunction-associated steatotic liver disease (MASLD) (aka non-alcoholic fatty liver disease), commonly occurring in individuals with obesity and type 2 diabetes can lead to liver inflammation/ fibrosis. MASLD results from fat being disproportionately deposited in the liver. The goal of this mechanistic study is to investigate metabolic response in patients aged 50 to 80 years with non-alcoholic fatty liver disease, after niacin (vitamin B3) treatment. The main questions it aims to answer are: * Does Niacin lower the fat deposition in the liver? * Does Niacin raise White Adipose Tissue storage of dietary fatty acids? Researchers will compare Niacin to a placebo (a look-alike substance that contains no drug) to compare the metabolic response. Duration of study per participant: Up to 28 weeks

Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)Liver Fibrosis/NASHNon-Alcoholic Steato-Hepatitis (NASH)

Université de Sherbrooke36 participantsStarted Apr 2026

Sherbrooke, Quebec, Canada

RECRUITING

3D-MRE and 2D-MRE for Assessing Cirrhosis and Portal Hypertension

NCT06205992

How to construct a novel, non-invasive, accurate, and convenient method to achieve prediction of hepatic venous pressure gradient (HVPG) is an important general problem in the management of portal hypertension in cirrhosis. We plan to compare the ability of three demensional-magnetic resonance elastography (3D-MRE) to two demensional-magnetic resonance elastography (2D-MRE) to establish a risk stratification system and perform tailored management for portal hypertension in cirrhosis.

CirrhosisLiver Portal Hypertension

Shengjing Hospital100 participantsStarted Aug 2022

Shenyang, Liaoning, China

Stimulating Fat Tissue Storage With Niacin to Reduce Fat Accumulation in the Liver.

3D-MRE and 2D-MRE for Assessing Cirrhosis and Portal Hypertension

Related Searches

Tocotrienol Against the Progression of End Stage Liver Disease

Impact of Circadian Exercise on Metabolic Dysfunction-Associated Steatotic Liver Disease in Postmenopausal Women

Treatment of Cirrhosis-related Hepatocellular Carcinoma With the Intrahepatic Arterial Injection of an Emulsion of Lipiodol and Idarubicin (Zavedos®): Phase I Study

Human Models of Selective Insulin Resistance: Pancreatic Clamp

Team Science (The Liver Health Study)

Using Autologous Bone Marrow Cells With Wharton Gel Exosomes to Stimulate Hepatic Cell Repair in Liver Cirrhosis

Quantitative Evaluation of the Progression of Liver Disease, Using ShearWaveTM

MHT and Liver Function in Postmenopausal Women

Breath Analysis Based Disease Biomarkers

Social & Contextual Impact on Children Undergoing Liver Transplantation

Sexual Dysfunction in Cirrhosis

A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

A Phase IIb Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Participants With Cirrhosis-ZEAL-UNLOCK

SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver Disease

Diagnosis of Lymphohistiocytic Hemophagocytosis in Intensive Care

Study of the Link Between MASH ( Metabolic Dysfunction-Associated Steatohepatitis) and MAMs (Mitochondria-Associated Membranes ) Alteration in Patients Undergoing Bariatric Surgery - MAMBA

Safety, Tolerability, and Bioeffects of Alirocumab in Non-treatment Seeking Heavy Drinkers

MAsS Scan as a Predictor of Morbidity and Mortality in Patients With Liver Disease